Journal
INFLAMMATORY BOWEL DISEASES
Volume 18, Issue 1, Pages 152-160Publisher
OXFORD UNIV PRESS INC
DOI: 10.1002/ibd.21870
Keywords
Crohn's disease; treatment consensus; mucosal healing; bowel preservation; TNF antagonists; infliximab; biologics
Categories
Funding
- Merck
- Sharp
- Dohme Corp., Whitehouse Station, NJ
- MSD
- Abbott
- Centocor
- Schering Canada
- Abbott Laboratories
- UCB
- SP
- Millenium
- Elan
- Proctor Gamble
- BMS Canada
Ask authors/readers for more resources
Background: Symptom relief is the traditional treatment goal in Crohn's disease (CD). New goals including mucosal healing and bowel preservation are now achievable with tumor necrosis factor (TNF) antagonists. Infliximab and adalimumab are approved as second-line treatments for severe, active CD. Certolizumab pegol is approved only in the U.S. and Switzerland as second-line treatment for moderate-to-severe, active CD. Data from trials of infliximab suggest that high-risk patients and patients with active inflammation (CRP elevation and/or ileocolonic ulcers) may benefit from earlier use of this drug.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available